ISSN: 1859 - 2872
Studying the expression of ER, PR, HER2, Ki67 markers in molecular subtypes of invasive breast carcinoma
Main Article Content
Keywords
Abstract
Objective: To determine the ratio of molecular types to breast cancer. To study the expression of ER, PR, HER2, Ki67 markers in breast cancer molecular types. Subject and method: 142 patients were diagnosed with breast cancer through needle biopsy or surgery at 108 Military Central Hospital. Primary tumor had not treated preoperative chemicals. The specimen was stained with 04 markers ER, PR, HER2, Ki67. Result: Type LUMA was the highest (28.9%), HER2 (17.6%), LUMB (15.5%), TNP (14.8%), and LAHH (16.2%), LBHH (7.0%). The radio positive of ER marker was higher than PR marker (65.5% and 37.3%). With HER2 marker, the actual positive HER2 ratio (3+) accounted for 47.6%. Ki67 index in types with good prognosis such as LUMA and LUMB tended to decrease from low Ki67 to high Ki67. Type TNP has Ki67 index increasing from low Ki67 to high Ki67. Conclusion: The expression of ER, PR, HER2 markers at different levels is meaningful in the molecular classification of breast cancer. The Ki67 index according to each type shows that the prognosis level decreases gradually in the order: LUMA, LUMB, LAHH, HER2, LBHH, TNP.
Article Details
References
2. Tạ Văn Tờ (2004) Nghiên cứu hình thái học, hóa mô miễn dịch và giá trị tiên lượng của chúng trong ung thư biểu mô tuyến vú. Luận án Tiến sĩ Y học, Trường Đại học Y Hà Nội.
3. Bhargava R, Esposito NN and Dabbs DJ (2010) Immunohistology of the breast. Diagnostic immunohistochemistry: Theranostic and genomic applications, 3rd Edition, Saunders, USA: 763-819.
4. Brenton JD, Carey LA, Ahmed AA and Caldas C (2005) Molecular classification and molecular forecasting of breast cancer: Ready for clinical application?. J Clin Oncol 23: 7350-60.
5. Goldhirsch A, Wood WC and Coates AS (2011) Strategies for subtypes-dealing with the diversity of breast cancer. Highlights of the St gallen international expert consensus on the primary therapy of early breast cancer 2011. Annals of Oncology 10: 1093.
6. Lakhani SR, Elis IO, Schnitt SJ et al (2012) WHO classification of tumors of the breast. IARC, Lyon, France.
7. Mohsin SK, Weiss H, Havighurst et al (2004) Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: A validation study. Modern Pathology 17: 1545-54.
8. Spitale A, Mazzola P, Soldini D et al (2009) Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Annals of Oncology 20: 628-635.
9. Tsutsui S, Yasuda K, Suzuki K et al (2006) Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer. BMC Cancer 6: 187.
Article Sidebar
